Vaccines are used to confer protection against a host of bacterial and viral pathogens that cause infections associated with high mortality and/or morbidity. Implementation of vaccination programs has had a revolutionary impact on global public health, leading to dramatic reductions in the incidence of infectious diseases, decreasing childhood and adult mortality rates, and drastically improving life expectancy and quality worldwide. In the United States, patients receive a wide range of vaccinations throughout adulthood, some of which not only prevent infections but also associated diseases (e.g., cervical cancer due to human papillomavirus [HPV]). The adult U.S. vaccine market continues to see launches of novel vaccines that prevent additional bacterial and viral infections. Despite notable competition, the adult segment remains an attractive market for the development of new vaccine options. This report focuses on five current vaccine indications (pneumococcal disease, meningococcal disease, HPV, herpes zoster [HZ], and flu) and associated patient demographics, patient share data, and current prescribing trends for these indications. For brands, product attributes that drive and constrain physician prescribing behavior are highlighted. Key attributes for emerging therapies are also explored.

Questions Answered in This Report:

  • Patient attributes, such as age, comorbidities, and health plan benefits are important drivers of vaccine administration among adult patients in the United States; further, brand preference and vaccination practices among adult populations are influenced by a variety of factors. What percentage of surveyed physicians’ adult patients (aged 15 or older) received a vaccine for particular diseases in the past 12 months? Are surveyed physicians familiar with the CDC’s Advisory Committee on Immunization Practices (ACIP) current vaccine recommendations and pediatric/adult immunization schedules? How strictly do surveyed physicians follow CDC/ACIP vaccine recommendations? Other than immunization guidelines/schedule, what factors impact physicians’ decisions to recommend vaccination or administer vaccines to adult patients (aged 15 or older)? What factors/attributes drive vaccine brand selection or preference?

  • U.S. patients have greater access to information about vaccines, a factor that is influencing their perceptions about vaccines and willingness to receive vaccines. In the past 12 months, what percentage of adult patients have requested information regarding a vaccine? For which vaccine-preventable disease(s) or condition(s) did patients request vaccines? Which brands did patients request? For which diseases or conditions have patients requested a vaccine because of direct-to-consumer (DTC) advertising? What percentage of patients decided to receive a vaccination following a physician recommendation? Does media coverage of vaccines drive patient perceptions?

  • Uptake of vaccines is driven by vaccine attributes that influence physician perception of brands, patient characteristics (e.g., age, underlying conditions), and general patient drivers and deterrents of vaccination. What are the leading brands across the five indications? What percentage of adult patients by age received vaccines for the five profiled indications in the past 12 months? How have vaccination rates for the profiled indications changed over the past 12 months? What is the anticipated use of select vaccine brands? What are the specific drivers and deterrents of vaccination across the five profiled indications? What is the size of the unvaccinated populations for the five profiled indications? For flu vaccines, what is the average year-over-year retention rate? For HPV, what is the discontinuation rate for the vaccine protocol or series, and what will be the extent of vaccination among previously HPV vaccination populations?

  • Multiple diseases have an unmet need for development of novel vaccines, including pan-influenza, Clostridium difficile, Staphylococcus aureus, human immunodeficiency virus (HIV), and herpes simplex virus-2 (HSV-2). Which of these indications has the highest unmet need? If a prophylactic vaccine for any one of these infectious diseases were to be approved by the FDA, what percentage of adult patients do physicians believe would receive it? What patient groups would receive the most benefit from a vaccine for one of these diseases?


Markets covered: United States.

Primary research: 100 U.S. physicians (51 primary care physicians and 49 infectious disease specialists) participated in an online survey.

Author(s): Michael Breen, Ph.D.